South Korea · Delayed Price · Currency is KRW CTCBIO Statistics
Total Valuation
CTCBIO has a market cap or net worth of KRW 88.58 billion. The enterprise value is 113.92 billion.
| Market Cap | 88.58B |
| Enterprise Value | 113.92B |
Important Dates
The last earnings date was Friday, March 27, 2026.
| Earnings Date | Mar 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CTCBIO has 23.91 million shares outstanding. The number of shares has decreased by -0.50% in one year.
| Current Share Class | 23.91M |
| Shares Outstanding | 23.91M |
| Shares Change (YoY) | -0.50% |
| Shares Change (QoQ) | -1.36% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.25% |
| Float | 21.34M |
Valuation Ratios
The trailing PE ratio is 27.02.
| PE Ratio | 27.02 |
| Forward PE | n/a |
| PS Ratio | 0.72 |
| PB Ratio | 1.15 |
| P/TBV Ratio | 1.24 |
| P/FCF Ratio | 24.63 |
| P/OCF Ratio | 20.21 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.91, with an EV/FCF ratio of 31.67.
| EV / Earnings | 35.16 |
| EV / Sales | 0.92 |
| EV / EBITDA | 8.91 |
| EV / EBIT | 18.23 |
| EV / FCF | 31.67 |
Financial Position
The company has a current ratio of 1.51, with a Debt / Equity ratio of 0.50.
| Current Ratio | 1.51 |
| Quick Ratio | 0.82 |
| Debt / Equity | 0.50 |
| Debt / EBITDA | 3.03 |
| Debt / FCF | 10.77 |
| Interest Coverage | 2.70 |
Financial Efficiency
Return on equity (ROE) is 4.34% and return on invested capital (ROIC) is 6.57%.
| Return on Equity (ROE) | 4.34% |
| Return on Assets (ROA) | 2.63% |
| Return on Invested Capital (ROIC) | 6.57% |
| Return on Capital Employed (ROCE) | 6.43% |
| Weighted Average Cost of Capital (WACC) | 3.99% |
| Revenue Per Employee | 499.07M |
| Profits Per Employee | 13.07M |
| Employee Count | 248 |
| Asset Turnover | 0.83 |
| Inventory Turnover | 2.42 |
Taxes
| Income Tax | -289.60M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -44.18% in the last 52 weeks. The beta is -0.11, so CTCBIO's price volatility has been lower than the market average.
| Beta (5Y) | -0.11 |
| 52-Week Price Change | -44.18% |
| 50-Day Moving Average | 4,139.80 |
| 200-Day Moving Average | 5,448.50 |
| Relative Strength Index (RSI) | 44.26 |
| Average Volume (20 Days) | 66,244 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CTCBIO had revenue of KRW 123.77 billion and earned 3.24 billion in profits. Earnings per share was 136.00.
| Revenue | 123.77B |
| Gross Profit | 49.96B |
| Operating Income | 6.25B |
| Pretax Income | 2.98B |
| Net Income | 3.24B |
| EBITDA | 12.78B |
| EBIT | 6.25B |
| Earnings Per Share (EPS) | 136.00 |
Balance Sheet
The company has 17.71 billion in cash and 38.74 billion in debt, with a net cash position of -21.03 billion or -879.69 per share.
| Cash & Cash Equivalents | 17.71B |
| Total Debt | 38.74B |
| Net Cash | -21.03B |
| Net Cash Per Share | -879.69 |
| Equity (Book Value) | 77.03B |
| Book Value Per Share | 3,083.77 |
| Working Capital | 23.36B |
Cash Flow
In the last 12 months, operating cash flow was 4.38 billion and capital expenditures -786.53 million, giving a free cash flow of 3.60 billion.
| Operating Cash Flow | 4.38B |
| Capital Expenditures | -786.53M |
| Depreciation & Amortization | 6.53B |
| Net Borrowing | 6.52B |
| Free Cash Flow | 3.60B |
| FCF Per Share | 150.43 |
Margins
Gross margin is 40.36%, with operating and profit margins of 5.05% and 2.62%.
| Gross Margin | 40.36% |
| Operating Margin | 5.05% |
| Pretax Margin | 2.41% |
| Profit Margin | 2.62% |
| EBITDA Margin | 10.33% |
| EBIT Margin | 5.05% |
| FCF Margin | 2.91% |
Dividends & Yields
CTCBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.50% |
| Shareholder Yield | 0.50% |
| Earnings Yield | 3.66% |
| FCF Yield | 4.06% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 22, 2013. It was a forward split with a ratio of 1.1.
| Last Split Date | Apr 22, 2013 |
| Split Type | Forward |
| Split Ratio | 1.1 |
Scores
CTCBIO has an Altman Z-Score of 2.08 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.08 |
| Piotroski F-Score | 6 |